UNSPSC 51282002: Bacitracin

This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 58H6RWO52I. European Medicines Agency schedules Bacitracin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00652MIG. Bacitracin generally arises in the molecular formula C66H103N17O16S. The term BACITRACIN is an International Non-Proprietary Name or INN. BACITRACIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51282002 Bacitracin, a Commodity code, encompasses topical antibiotic products that state and local healthcare facilities procure through cooperative purchasing agreements and multistate pharmaceutical contracts. Recent activity shows governments buying bacitracin as part of broader generic pharmaceuticals and over-the-counter product portfolios supplied through authorized wholesalers, rather than as single-line-item procurements. The issuing bodies soliciting under this code are state health departments and multistate cooperative purchasing alliances that aggregate demand across participating state agencies, local health systems, and other government facilities.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response date of March 26, 2026. The contract covers participating states including Oregon and encompasses bacitracin as one of many NDC-coded products in a comprehensive pharmaceutical portfolio. Awarded vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and maintain contractual relationships with at least two of the three. Evaluation weighs price competitiveness at 75 percent, with secondary criteria including fixed pricing (10 percent), price-format flexibility such as WAC-minus pricing (5 percent), EDI capability (5 percent), and compliance with administrative fee data requirements (5 percent). Products must be available by May 15, 2026, with resulting agreements effective July 1, 2026. Vendors must certify cGMP and Drug Supply Chain Security Act compliance, maintain $5 million commercial general liability coverage, and agree to a 3 percent administrative fee on all contract purchases.